For example, the SGLT2 inhibitors (a class of glucose-lowering drugs) have been recommended for treatment of heart failure due to their robust cardioprotective effects via likely mechanisms of lowering cellular NADH/NAD+ ratio and activating Nrf2-mediated antioxidant pathways [28,29]. Here, SLC5A2 is linked to heart failure.